Nonclinical precedent Request an invite
Species
Cynomolgus monkey only
“Emicizumab was shown to bind similarly to the corresponding cynomolgus monkey coagulation factors, as such the cynomolgus monkey is a pharmacologically relevant species.”
✓ VerifiedFDA multi-discipline review, p. 25Source ↗
Why that species
Binds/activates cynomolgus FIX/FX comparably to human; no FX activation with mouse or rat factors
“In an enzyme assay using purified Cynomolgus monkey, rat and mouse FIXa and FX, emicizumab was found to cross-react only with the corresponding clotting factors of Cynomolgus monkeys.”
✓ VerifiedEMA assessment report, p. 28Source ↗
Surrogate molecule
No surrogate; clinical molecule tested in monkey (FVIII-neutralizing antibodies used only to create hemophilia models)
“Emicizumab was generally well tolerated in a 26-week toxicology study conducted in cynomolgus monkeys administered weekly SC doses of emicizumab at 1, 6, and 30 mg/kg.”
✓ VerifiedFDA multi-discipline review, p. 26Source ↗
Species: general tox
Cynomolgus monkey only
“Emicizumab was generally well tolerated in a 26-week toxicology study conducted in cynomolgus monkeys administered weekly SC doses of emicizumab at 1, 6, and 30 mg/kg.”
✓ VerifiedFDA multi-discipline review, p. 26Source ↗
Species: DART
Not conducted (hemophilia A is X-linked recessive)
“Animal reproductive and developmental toxicology studies were not conducted with emicizumab as hemophilia A is inherited in an X-linked recessive manner.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: carcinogenicity
Not conducted (no pharmacologically relevant rodent species)
“Carcinogenicity studies were not conducted due to lack of a pharmacologically relevant rodent species.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Surrogate used in
No surrogate used; clinical molecule tested in cynomolgus monkey
“Emicizumab was shown to bind similarly to the corresponding cynomolgus monkey coagulation factors, as such the cynomolgus monkey is a pharmacologically relevant species.”
✓ VerifiedFDA multi-discipline review, p. 25Source ↗

Same question, other multispecifics

Bizengri

zenocutuzumab · HER2 x HER3
Cynomolgus monkey only

Blincyto

blinatumomab · CD19 x CD3
Chimpanzee (only relevant species, limited non-terminal studies) plus mouse with murine surrogate

Columvi

glofitamab · CD20 x CD3
Cynomolgus monkey only

Elrexfio

elranatamab · BCMA x CD3
Cynomolgus monkey only

Epkinly

epcoritamab · CD20 x CD3
Cynomolgus monkey only

Imdelltra

tarlatamab · DLL3 x CD3
Cynomolgus monkey (pivotal); mouse surrogate muS757 for EFD and 1-month study

Kimmtrak

tebentafusp · CD3 x gp100 (TCR fusion)
No relevant species; in vitro human cell/tissue assays only

Korjuny

catumaxomab · EpCAM x CD3
No relevant species; limited single-dose mouse, rat, one cynomolgus; BiLu mouse surrogate

Lunsumio

mosunetuzumab · CD20 x CD3
Cynomolgus monkey only

Lynozyfic

linvoseltamab · BCMA x CD3
Cynomolgus monkey only

Ordspono

odronextamab · CD20 x CD3
Cynomolgus monkey only

Removab

catumaxomab · EpCAM x CD3
No relevant species; in vitro human cells plus mouse surrogate (BiLu); limited single-dose rodent/monkey

Rybrevant

amivantamab · EGFR x MET
Cynomolgus monkey only

Talvey

talquetamab · GPRC5D x CD3
Cynomolgus monkey only (tool molecule for pivotal tox); no rodent tox

Tecvayli

teclistamab · BCMA x CD3
Cynomolgus monkey only (rabbit used for SC local tolerance only)

Vabysmo

faricimab · VEGF-A x Ang-2
Cynomolgus monkey only for pivotal tox (rabbit dropped after early studies)

Ziihera

zanidatamab · HER2 x HER2 (biparatopic)
Cynomolgus monkey only

Summary across all 18 multispecifics →